Constructs for chimeric antigen receptors
Inventors
KLICHINSKY, Michael • Minutolo, Nicholas G. • Anderson, Nicholas R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure pertains to immune cells comprising chimeric antigen receptors (CARs) and methods of using immune cells comprising CARs.
Core Innovation
A macrophage or monocyte comprises a chimeric antigen receptor having an extracellular domain, a CD28-derived extracellular hinge domain, a CD28 transmembrane domain, and an intracellular domain. The cell exhibits increased tumor-killing ability relative to a macrophage or monocyte comprising a similar CAR with a CD8 hinge domain. CAR configurations encompass antigen-binding domains, Fc receptor or toll-like receptor domains, and intracellular signaling domains.
A nucleic acid construct encoding the CD28-hinge CAR modifies a macrophage or monocyte to produce a cell with increased tumor-killing ability. Delivery associated with Vpx increases CAR expression and persistence while modified cells retain viability, and reduction or deletion of SIRP̵̵α enhances phagocytosis and tumor-cell killing. The problem being solved is not explicitly described in the patent because the background section is omitted.
Claims Coverage
The claims define two inventive features based on two independent claims covering an engineered cell and a method of cellular modification.
Macrophage or monocyte comprising a CD28-hinge CAR
An independent claim recites a macrophage or monocyte comprising a CAR with an extracellular domain, a CD28-derived extracellular hinge domain, a CD28 transmembrane domain, and an intracellular domain, wherein the cell exhibits increased tumor killing ability relative to a macrophage or monocyte comprising a similar CAR with a CD8 hinge domain. Dependent claims specify scFv, centyrin, darpin, or Fc receptor domains, a CD3-zeta domain, increased TNFα production, and a pharmaceutical composition.
Modification of a macrophage or monocyte with a CD28-hinge CAR
An independent claim recites delivering a nucleic acid construct encoding a CAR with an extracellular domain, a CD28 extracellular hinge domain, a CD28 transmembrane domain, and an intracellular domain to a macrophage or monocyte, yielding a cell with increased tumor killing ability relative to a similar CD8-hinge CAR cell. Dependent claims specify viral delivery with Vpx, co-treatment with a CD40 agonist or a 4-1BB-ligand agonist, and reduced SIRPα activity or deletion.
The claims cover a CD28-hinge CAR-expressing macrophage or monocyte and methods of modifying cells with a construct encoding the receptor, each exhibiting increased tumor-killing ability compared to a CD8-hinge counterpart.
Stated Advantages
Increased tumor-killing ability relative to a macrophage or monocyte comprising a similar CAR with a CD8 hinge domain.
Increased TNFα production relative to a macrophage or monocyte comprising a similar CAR with a CD8 hinge domain.
Increased CAR expression and persistence in modified cells receiving viral-vector CAR delivery with Vpx compared to delivery without Vpx.
Enhanced phagocytosis and tumor-cell killing resulting from reduction or deletion of SIRPα.
Documented Applications
A pharmaceutical composition comprising the claimed macrophage or monocyte and a pharmaceutically acceptable carrier.
Functional tumor-cell killing, tumor-growth inhibition, and tumor-burden assays involving CAR-engineered macrophages and CRL2351 or SKOV3 tumor cells.
Therapeutic applications of CAR-modified macrophages and monocytes in cancer and other disorders.
Interested in licensing this patent?